Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDSNASDAQ:CYCCNASDAQ:ENSCNASDAQ:OTIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00$0.00$0.00▼$0.08$5K12.428,169 shs160 shsCYCCCyclacel Pharmaceuticals$3.59-11.5%$4.28$0.25▼$49.34$744.34M0.52101,058 shs160,429 shsENSCEnsysce Biosciences$2.19+0.9%$2.88$1.62▼$14.67$5.19M1.09908,076 shs135,827 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%0.00%0.00%-99.00%-99.83%CYCCCyclacel Pharmaceuticals0.00%-93.68%-93.36%-95.05%-99.30%ENSCEnsysce Biosciences0.00%-15.56%+6.90%-62.59%-72.39%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.4132 of 5 stars0.05.00.00.02.92.50.0ENSCEnsysce Biosciences0.1567 of 5 stars0.02.00.00.02.60.00.0OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/ACYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/AOTICOtonomy 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis Pharmaceuticals$3.09M0.00N/AN/AN/A∞CYCCCyclacel Pharmaceuticals$43K17,310.15N/AN/A$0.57 per share6.30ENSCEnsysce Biosciences$2.23M2.33N/AN/A($3.10) per share-0.71OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/A5/12/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$3.50N/A∞N/A-18,150.00%-1,901.11%-188.23%5/12/2025 (Estimated)ENSCEnsysce Biosciences-$10.61M-$13.39N/AN/AN/A-179.26%-292.81%-158.83%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ALatest OTIC, CYCC, ENSC, and ARDS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04N/A$0.03 millionN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/10/2025Q4 2024ENSCEnsysce Biosciences-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals$0.154.18%N/AN/A N/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ALatest OTIC, CYCC, ENSC, and ARDS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDSAridis PharmaceuticalsN/AN/AN/ACYCCCyclacel PharmaceuticalsN/A0.770.77ENSCEnsysce BiosciencesN/A3.243.24OTICOtonomyN/A1.741.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%CYCCCyclacel Pharmaceuticals23.58%ENSCEnsysce Biosciences5.63%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%CYCCCyclacel Pharmaceuticals68.00%ENSCEnsysce Biosciences7.90%OTICOtonomy1.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableCYCCCyclacel Pharmaceuticals14207.34 million4.78 millionOptionableENSCEnsysce Biosciences102.37 million1.20 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableOTIC, CYCC, ENSC, and ARDS HeadlinesRecent News About These CompaniesOtonomy's hearing loss drug shows no benefit in trial, tanking sharesSeptember 3, 2024 | pharmaphorum.comTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023April 21, 2024 | straight.comAllergic Contact Dermatitis and Topical AntibioticsSeptember 10, 2023 | medscape.comHearing Loss in AdultsAugust 21, 2023 | nejm.orgResearch PublicationsAugust 4, 2023 | slu.eduManagement of Pediatric Otitis MediaMay 11, 2023 | medscape.comHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRMay 8, 2023 | news.google.comAlluvial Capital Management Q1 2023 Letter To Partners - Seeking AlphaApril 28, 2023 | news.google.comVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital JournalApril 27, 2023 | news.google.comHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRApril 25, 2023 | news.google.comENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital JournalApril 24, 2023 | news.google.comHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital JournalApril 11, 2023 | news.google.comENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital JournalApril 10, 2023 | news.google.com[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital JournalApril 10, 2023 | news.google.comHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital JournalApril 3, 2023 | news.google.comHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints NewsMarch 30, 2023 | news.google.comAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints NewsMarch 30, 2023 | news.google.comMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints NewsMarch 30, 2023 | news.google.comBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints NewsMarch 30, 2023 | news.google.comSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints NewsMarch 30, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTIC, CYCC, ENSC, and ARDS Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0001 0.00 (0.00%) As of 05/9/2025 10:51 AM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Cyclacel Pharmaceuticals NASDAQ:CYCC$3.59 -0.46 (-11.45%) Closing price 04:00 PM EasternExtended Trading$3.68 +0.09 (+2.40%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Ensysce Biosciences NASDAQ:ENSC$2.19 +0.02 (+0.92%) Closing price 04:00 PM EasternExtended Trading$2.17 -0.02 (-0.91%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
